RESUMEN
INTRODUCTION: Rare acquired bleeding disorders include a wide spectrum of coagulopathies characterized by spontaneous or post-trauma and post-surgery hemorrhages in patients without a previous personal or family history of bleeding. AREAS COVERED: This review, based on a Medline/PubMed search during the last 20 years, will focus mainly on rare acquired bleeding disorders caused by autoantibodies against coagulation factors, including autoantibodies against factor VIII (acquired hemophilia A), von Willebrand factor (acquired von Willebrand syndrome) and other coagulation factors (factors V, X, XI, and XIII). The pathogenic, laboratory, and clinical features of these rare hemorrhagic conditions will be discussed, with particular attention to their management. EXPERT OPINION: The treatment of rare acquired bleeding disorders includes the control of bleeding and the elimination of the autoantibody and of the underlying disease, when present. As the bleeding clinical phenotype is often severe, the management of affected patients is particularly challenging. Thus, while an early diagnosis of the acquired coagulopathy is essential to start the most appropriate treatment and to improve patients' outcomes, the support of specialized centers is equally important to provide a correct management of such complicated cases.
Asunto(s)
Autoanticuerpos , Inhibidores de Factor de Coagulación Sanguínea , Factores de Coagulación Sanguínea , Hemofilia A , Enfermedades Raras , Enfermedades de von Willebrand , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Inhibidores de Factor de Coagulación Sanguínea/sangre , Inhibidores de Factor de Coagulación Sanguínea/inmunología , Factores de Coagulación Sanguínea/inmunología , Factores de Coagulación Sanguínea/metabolismo , Hemofilia A/sangre , Hemofilia A/inmunología , Humanos , Enfermedades Raras/sangre , Enfermedades Raras/inmunología , Enfermedades de von Willebrand/sangre , Enfermedades de von Willebrand/inmunologíaRESUMEN
We report the case of a French woman with acquired von Willebrand syndrome who presents recurrent subarachnoid and intra-cerebral hemorrhage since 2012. She had no family or personal bleeding history. In the biologic explorations, APTT was abnormally high with no anticoagulant drugs (it was normal, historically). Two monoclonal IgG and IgM kappa proteins were detected without any lymphoproliferative disorder. Intravenous infusion of immunoglobulin is very effective in AVWS with immunoglobulin G monoclonal gammapathie of undetermined significance. We had a satisfactory correction of coagulation factors for about 30 days. The exploration of APTT is surely essential for the diagnosis and treatment.
Asunto(s)
Hemorragia Cerebral/etiología , Gammopatía Monoclonal de Relevancia Indeterminada/inmunología , Enfermedades de von Willebrand/diagnóstico , Anciano , Autoanticuerpos/inmunología , Pruebas de Coagulación Sanguínea , Hemorragia Cerebral/diagnóstico por imagen , Hemorragia Cerebral/prevención & control , Epistaxis/etiología , Femenino , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Cadenas kappa de Inmunoglobulina/sangre , Inmunoglobulinas Intravenosas/uso terapéutico , Imagen por Resonancia Magnética , Gammopatía Monoclonal de Relevancia Indeterminada/complicaciones , Neuroimagen , Paraproteínas/análisis , Recurrencia , Hemorragia Subaracnoidea/diagnóstico por imagen , Hemorragia Subaracnoidea/etiología , Enfermedades de von Willebrand/etiología , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/terapia , Factor de von Willebrand/uso terapéuticoAsunto(s)
Manejo de la Enfermedad , Isoanticuerpos , Enfermedades de von Willebrand/patología , Adulto , Factor VIIa/administración & dosificación , Femenino , Humanos , Transfusión de Plaquetas , Embarazo , Resultado del Embarazo , Ácido Tranexámico/administración & dosificación , Enfermedades de von Willebrand/inmunología , Factor de von Willebrand/inmunologíaRESUMEN
OBJECTIVES: Acquired von Willebrand syndrome (AvWS) is associated with postoperative bleeding complications in patients with continuous flow left ventricular assist devices (CF-LVADs). The aim of this study is to analyze the perioperative vWF profile comparing an axial pump (HMII) to a centrifugal pump (HVAD) regarding the correlation between perioperative occurrence of AvWS, early- and late-postoperative bleeding events. METHODS: From July 2013 until March 2015 blood samples of 33 patients (12 HMII/ 8 HVAD/ 13 controls) were prospectively collected at 12 different time points and analyzed for the vWF antigen (vWF:Ag), its activity (vWF:Ac) and the vWF:Ac/vWF:Ag-ratio (vWF:ratio). The follow up period for postoperative bleeding events was from July 2013 until July 2016. RESULTS: Postoperatively, there was no difference in the vWF-profile between HVAD and HMII groups. However, a subgroup of patients already had significantly lower vWF:ratios preoperatively. Postoperatively, both CF-LVAD groups presented significantly lower vWF:ratios compared to the control group. Bleeding events per patient-year did not differ between the two groups (HMII vs. HVAD: 0.67 vs. 0.85, p = 0.685). We detected a correlation between vWF:ratio <0.7at LVAD-start (r = -0.583, p = 0.006) or at the end of surgery (r = -0.461, p = 0.035) and the occurrence of pericardial tamponade. In the control group, the drop in both vWF:Ag and vWF:Ac recovered immediately postoperatively above preoperative values. CONCLUSION: A subgroup of patients with end-stage heart failure already suffers AvWS preoperatively. In both CF-LVAD groups, AvWS begins immediately after surgery. Intraoperative vWF:ratios <0.7 correlate with higher incidences of pericardial tamponade and re-operation. The presumably dilutive effect of the heart lung machine on vWF vanishes immediately at the end of surgery, possibly as part of an acute-phase response.
Asunto(s)
Puente de Arteria Coronaria/efectos adversos , Insuficiencia Cardíaca/sangre , Hemorragia Posoperatoria/sangre , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/metabolismo , Anciano , Antígenos/sangre , Antígenos/inmunología , Femenino , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/cirugía , Corazón Auxiliar/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Periodo Perioperatorio/efectos adversos , Hemorragia Posoperatoria/etiología , Hemorragia Posoperatoria/fisiopatología , Enfermedades de von Willebrand/etiología , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/fisiopatología , Factor de von Willebrand/inmunologíaAsunto(s)
Trastornos Hemorrágicos/terapia , Factor VIII/antagonistas & inhibidores , Factor VIII/inmunología , Factor VIII/uso terapéutico , Hemofilia A/inmunología , Hemofilia A/terapia , Trastornos Hemorrágicos/inmunología , Humanos , Terapia de Inmunosupresión , Plasma , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/terapiaRESUMEN
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. Bleeding scores in VWD, focused in particular on mucosal bleeding, can be very useful in the diagnosis and validation of different types of treatment. The results of an extended prospective study with a large amount of information on clinical phenotype and implications in treatment are reviewed in this article. Treatment of mucosal and joint bleeding in severe VWD remains difficult in some patients. Due to the lack of data on the use of prophylaxis in these patients it is difficult to establish optimal treatment regimens. An overview of the literature, with a focus on the ongoing PRO.WILL study, is provided here. Furthermore, understanding the changes in von Willebrand factor (VWF) levels during pregnancy is very important for establishing the optimal management strategy for pregnancy and delivery in women with VWD. A recently published prospective observational cohort study in women with and without VWD during the postpartum period provides important data that should allow the improvement of postpartum treatment protocols.
Asunto(s)
Hemofilia A/inmunología , Hemofilia A/mortalidad , Tolerancia Inmunológica , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/terapia , Anciano , Factor VIII/química , Costos de la Atención en Salud , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades de von Willebrand/mortalidad , Factor de von Willebrand/químicaRESUMEN
Animal models of inherited bleeding disorders are important for understanding disease pathophysiology and are required for preclinical assessment of safety prior to testing of novel therapeutics in human and veterinary medicine. Experiments in these animals represent important translational research aimed at developing safer and better treatments, such as plasma-derived and recombinant protein replacement therapies, gene therapies and immune tolerance protocols for antidrug inhibitory antibodies. Ideally, testing is done in animals with the analogous human disease to provide essential safety information, estimates of the correct starting dose and dose response (pharmacokinetics) and measures of efficacy (pharmacodynamics) that guide the design of human trials. For nearly seven decades, canine models of hemophilia, von Willebrand disease and other inherited bleeding disorders have not only informed our understanding of the natural history and pathophysiology of these disorders but also guided the development of novel therapeutics for use in humans and dogs. This has been especially important for the development of gene therapy, in which unique toxicities such as insertional mutagenesis, germ line gene transfer and viral toxicities must be assessed. There are several issues regarding comparative medicine in these species that have a bearing on these studies, including immune reactions to xenoproteins, varied metabolism or clearance of wild-type and modified proteins, and unique tissue tropism of viral vectors. This review focuses on the results of studies that have been performed in dogs with inherited bleeding disorders that closely mirror the human condition to develop safe and effective protein and gene-based therapies that benefit both species.
Asunto(s)
Modelos Animales de Enfermedad , Terapia Genética/efectos adversos , Terapia Genética/métodos , Hemofilia A/terapia , Animales , Perros , Técnicas de Transferencia de Gen , Vectores Genéticos , Mutación de Línea Germinal , Hemofilia A/sangre , Hemofilia A/inmunología , Hemorragia/inmunología , Humanos , Tolerancia Inmunológica , Ratones , Mutagénesis , Primates , Proteínas Recombinantes/química , Enfermedades de von Willebrand/inmunologíaRESUMEN
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow. Generally, this predisposes the elderly to thrombosis rather than bleeding. It often necessitates antiplatelet or anticoagulation therapy, which can cause significant bleeding problems in an aging population. Additionally, changing renal function, modification in immune regulation, and a multitude of other disease processes, can give rise to acquired bleeding disorders. Bleeding can prove difficult to treat in a dynamic environment and in a population that may have underlying thrombotic risk factors.This article discusses some specific challenges of acquired bleeding arising in the elderly. The use of anticoagulation and nonsteroidal anti-inflammatory medications is prevalent in the treatment of the elderly and predisposes them to increased bleeding risk as their physiology changes. When prescribing and monitoring these therapies, it is exceedingly important to weigh thrombotic versus bleeding risks. There are additional rare acquired bleeding disorders that predominantly affect the elderly. One of them is acquired hemophilia, which is an autoimmune disorder arising from antibodies against factor VIII. The treatment challenge rests in the use of hemostatic agents in a population that is already at increased risk for thrombotic complications. Another rare disorder of intensifying interest, acquired von Willebrand syndrome, has a multitude of etiologic mechanisms. Understanding the underlying pathophysiology is essential in making a treatment decision for this disorder.
Asunto(s)
Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Hemorragia/tratamiento farmacológico , Anciano , Envejecimiento , Animales , Anticoagulantes/uso terapéutico , Trastornos de la Coagulación Sanguínea/diagnóstico , Ensayos Clínicos como Asunto , Comorbilidad , Toma de Decisiones , Factor VIII/inmunología , Hemofilia A/terapia , Hemorragia/diagnóstico , Hemostasis , Humanos , Hipotiroidismo/patología , Sistema Inmunológico , Terapia de Inmunosupresión , Inflamación , Enfermedades Renales/patología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Factores de Riesgo , Porcinos , Trombosis , Enfermedades de von Willebrand/inmunologíaRESUMEN
Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder similar to inherited von Willebrand disease. We describe a 78-year-old woman with coexistent idiopathic thrombocytopenic purpura (ITP) and AVWS. The patient had once been admitted to our hospital because of cerebral infarction. Her platelet count had been normal at that time. Ten years later, she showed a severe bleeding tendency (platelet count 3.2×10(4)/µl). Analysis of hemostatic parameters showed very low (<6%) von Willebrand factor ristocetin cofactor (vWF: Rco), and low VIII: C (22%), but elevated (276%) von Willebrand antigen. Electrophoretic analysis of plasma showed low levels of the high-molecular weight VWF multimer. The presence of antibodies (IgG1 and IgG4) to VWF was detected by enzyme linked immunosorbent assay (ELISA). Factor XIII activity was 42%. Treatment with corticosteroids did not improve the thrombocytopenia, but did correct the bleeding diathesis. Also, VWF: Rco and VIII: C showed normalization. These findings indicated that the patient had ITP associated with AVWS. All reported cases of AVWS associated with systemic lupus erythematosus were cured by appropriate treatment of the underlying autoimmune disease with prednisone or immunosuppression. This bleeding disorder occurs mainly in patients with lymphoproliferative, myeloproliferative, cardiovascular and immunologic disorders, but no patients with ITP have previously been reported. This patient had the rare presentation of AVWS complicated by ITP and factor XIII deficiency.
Asunto(s)
Púrpura Trombocitopénica Idiopática/complicaciones , Enfermedades de von Willebrand/inmunología , Anciano , Anticuerpos/inmunología , Resultado Fatal , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedades de von Willebrand/tratamiento farmacológico , Factor de von Willebrand/inmunologíaRESUMEN
INTRODUCTION: von Willebrand disease (VWD) is reportedly the most common bleeding disorder and arises from deficiency and/or defects of von Willebrand factor (VWF). Laboratory diagnosis and typing has important management implications and requires a wide range of tests, including VWF activity and antigen, and involves differential identification of qualitative vs quantitative defects. METHODS: We have assessed several VWF antigen and activity assays (collagen binding [VWF:CB], ristocetin cofactor [VWF:RCo] and the new Siemens INNOVANCE assay [VWF:Ac], employing latex particles and gain of function recombinant glycoprotein Ib to facilitate VWF binding and agglutination without need for ristocetin) using different instrumentation, including the new Sysmex CS-5100, with a large sample test set (n=600). We included retrospective plus prospective study designs, and also evaluated desmopressin responsiveness plus differential sensitivity to high molecular weight VWF. RESULTS: VWF:Ag and VWF:RCo results from different methods were respectively largely comparable, although some notable differences were evident, including one high false normal VWF:Ag value (105 U/dL) on a type 3 VWD sample, possibly due to heterophile antibody interference in the latex-based CS-5100 methodology. VWF:Ac was largely comparable to VWF:RCo, but VWF:CB showed discrepant findings to both VWF:RCo and VWF:Ac with some patients, most notably patients with type 2M VWD. CONCLUSIONS: (a) VWF:Ag on different platforms are largely interchangeable, as are VWF:RCo on different platforms, except for occasional (some potentially important) differences, and manufacturer recommended methods may otherwise require some assay optimization; (b) VWF:RCo and VWF:Ac are largely interchangeable, except for occasional differences that may also relate to assay design (differing optimizations); (c) VWF:CB provides an additional activity to supplement VWF:RCo or VWF:Ac activity assays, and is not interchangeable with either.
Asunto(s)
Diagnóstico por Computador/métodos , Inmunoensayo/métodos , Enfermedades de von Willebrand/sangre , Enfermedades de von Willebrand/diagnóstico , Factor de von Willebrand/inmunología , Humanos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Enfermedades de von Willebrand/inmunologíaRESUMEN
BACKGROUND: Acquired von Willebrand Syndrome is a rare bleeding disorder, which arises in individuals with no personal or family history of bleeding, associated with lymphoproliferative and myeloproliferative disorders or other diseases. AIM: To develop a two-step approach assay to detect autoantibodies against VWF and to verify their prevalence in AVWS. METHODS: AVWS definition: negative personal or family history of bleeding diathesis, VWF below normal range and recent history of bleeding manifestations. Twenty-three consecutive patients affected by AVWS were enrolled. An ELISA assay (first step) using recombinant VWF protein immobilized on plates and sheep/goat polyclonal anti-human IgG or IgM labelled with peroxidase was developed. A group of 40 healthy subjects was tested to calculate the floating cut point value. A confirmation assay (with addition of purified VWF vs buffer) was performed (second step). RESULTS: Twenty-one patients (93%) had an associated disease, two patients had idiopathic AVWS. Anti-VWF autoantibodies were detected in 9 patients (39%). Of these, eight (89%) had VWF:RCo levels <10%, but none of them resulted positive using Bethesda assay (neutralizing antibodies). The confirmation test confirmed the positive results obtained with ELISA and resulted negative in those patients with negative results and in the controls. CONCLUSION: With the present two-step approach assay nine out of 23 (39%) patients affected with AVWS resulted positive for anti-VWF autoantibodies. This ELISA assay might be used as an additional confirmation tool in the diagnostic procedure in patients affected by AVWS or in the follow-up of congenital and acquired patients exposed to replacement therapy.
Asunto(s)
Autoanticuerpos/sangre , Ensayo de Inmunoadsorción Enzimática/métodos , Enfermedades de von Willebrand/diagnóstico , Enfermedades de von Willebrand/inmunología , Factor de von Willebrand/inmunología , Anciano , Biomarcadores/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y EspecificidadRESUMEN
Haemostatic management of surgery in patients with von Willebrand disease (VWD) includes DDAVP or von Willebrand factor (VWF)-containing concentrates. Although the recommendations are for monitoring by VWF activity assays, it is quite common for clinicians to use factor VIII due usually to longer turnaround times required for VWF ristocetin cofactor assay (VWF:RCo) measurements. The aim of this study was to evaluate use of the rapid HaemosIL VWF activity (VWF:Act) latex immuno assay (LIA) on an automated coagulometer (ACL TOP(™) 700; Instrumentation Laboratory, Bedford, MA, USA) compared to platelet-based VWF:RCo assays in this setting. One hundred and sixty-seven plasma samples from 42 patients [Type 1 (n = 22), Type 2A (n = 2), Type 2B (n = 3), Type 2M (n = 10), Type 3 (n = 3)] and acquired von Willebrand syndrome (n = 2) with VWD treated with DDAVP or VWF-containing concentrates were included in the study. Method comparison and method bias were evaluated by Bland-Altman analysis (BA) and Passing and Bablok regression modelling respectively. BA of baseline samples (n = 39) showed a mean difference of -3.0 (±1.96 SD -25.2 to +19.4). Post (treatment) samples (n = 120) were separated into two groups. Group 1 contained samples with VWF:RCo levels 10 to ≤175 IU dL(-1) (n = 97) and group 2, samples with VWF:RCo levels >175 IU dL(-1) (n = 23). BA of group 1 postsamples showed a mean difference of +3.4 (±1.96 SD -44.6 to +51.5), and the BA of Group 2 samples was -23.9 (±1.96 SD -136.1 to +88.3). In conclusion, use of HaemosIL VWF:Act LIA test on an automated coagulometer is a reproducible and rapid assay that can be used as an alternative test for monitoring VWF replacement therapy, facilitating dose adjustments on a real-time basis.
Asunto(s)
Desamino Arginina Vasopresina/uso terapéutico , Inmunoensayo/métodos , Látex , Enfermedades de von Willebrand/tratamiento farmacológico , Enfermedades de von Willebrand/inmunología , Factor de von Willebrand/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Plaquetas/efectos de los fármacos , Plaquetas/inmunología , Niño , Preescolar , Femenino , Liofilización , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven , Enfermedades de von Willebrand/sangreAsunto(s)
Gammopatía Monoclonal de Relevancia Indeterminada/complicaciones , Enfermedades de von Willebrand/etiología , Anciano de 80 o más Años , Hemorragia Gingival/etiología , Humanos , Inmunoglobulina G/sangre , Cadenas lambda de Inmunoglobulina/sangre , Isoanticuerpos/sangre , Isoanticuerpos/inmunología , Masculino , Agregación Plaquetaria , Ristocetina/farmacología , Enfermedad de von Willebrand Tipo 3/sangre , Enfermedades de von Willebrand/diagnóstico , Enfermedades de von Willebrand/inmunologíaRESUMEN
VWD is the most common inherited bleeding disorder known. It is caused by a deficiency or dysfunction of the VWF molecule. Bleeding risk varies between modest increases in bleeding seen only with procedures to major risk of spontaneous hemorrhage depending upon the type of VWD. The treatment approach to VWD has changed little in the past 2 decades, but there are numerous subtleties in optimal management. Management includes the prevention or treatment of bleeding by raising endogenous VWF levels with medications such as desmopressin or providing exogenous VWF concentrates. Fibrinolytic inhibitors and topical hemostatic agents are also effective adjunctive measures. Bleeding specific to women presents a special challenge because of heavy menstrual bleeding and pregnancy. Successful management of pregnancy in patients with VWD involves coordination with obstetrics, anesthesia, and the coagulation laboratory monitoring VWF:RCo and FVIII:C levels. Prophylactic treatment with VWF concentrates is emerging as an effective preventive therapy in patients with severe disease. Antibodies to VWF present a special challenge in the management of rare patients with type 3 disease. New therapies on the horizon include recombinant VWF, anti-VWF aptamers, and medications such as IL-11 to raise VWF levels. The key to effective treatment of VWD is an accurate diagnosis of the specific type and selection of hemostatic products appropriate for the clinical situation.
Asunto(s)
Enfermedades de von Willebrand/terapia , Quimioterapia Adyuvante , Femenino , Humanos , Isoanticuerpos/inmunología , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/prevención & control , Factor de von Willebrand/biosíntesisRESUMEN
Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of congenital von Willebrand disease. We herein report a case of AVWS associated with Hashimoto's thyroiditis and subcutaneous mucosa-associated lymphoid tissue lymphoma. An IgG autoantibody against von Willebrand factor (VWF) was detected. The antibody bound to VWF but did not inhibit VWF activity. Rapid clearance of VWF seemed to be the cause of AVWS in the present case. VWF-containing concentrates stopped the bleeding. Even if such a complication is rare, for AVWS patients, prompt recognition of the underlying mechanism can save lives.
Asunto(s)
Enfermedad de Hashimoto/complicaciones , Linfoma de Células B de la Zona Marginal/complicaciones , Enfermedades de von Willebrand/etiología , Autoanticuerpos/sangre , Femenino , Enfermedad de Hashimoto/inmunología , Humanos , Inmunoglobulina G/sangre , Persona de Mediana Edad , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/terapia , Factor de von Willebrand/administración & dosificación , Factor de von Willebrand/inmunología , Factor de von Willebrand/metabolismoRESUMEN
The development of alloantibodies against von Willebrand factor (VWF) represents a rare but serious complication of treatment of von Willebrand disease (VWD), occurring in ~5% to 10% of type 3 VWD patients. Affected patients can present with a range of symptoms, including lack or loss of hemostatic response to infused VWF concentrates up to anaphylactic reactions in rare cases. It is classically reported in multitransfused patients and occurs most frequently in patients with partial or complete VWF gene deletions. A positive family history of anti-VWF antibodies also appears to be a risk factor. There is a lack of standardization of laboratory methods for antibody identification and characterization. Issues of variability in laboratory approaches as well as the rarity of the complication act as a barrier to future studies. Recombinant factor VIII as well as bypassing agents and immune tolerance have been reported as effective treatments; however, aside from case reports, little exists in the literature to guide management. The imminent clinical availability of recombinant VWF has prompted a resurgence of interest in this area. Additional study is warranted to address the deficiencies in our understanding of this treatment complication.
Asunto(s)
Isoanticuerpos/metabolismo , Enfermedades de von Willebrand/inmunología , Factor VIII/uso terapéutico , Humanos , Isoanticuerpos/efectos adversos , Isoanticuerpos/sangre , Enfermedades de von Willebrand/diagnóstico , Enfermedades de von Willebrand/epidemiología , Enfermedades de von Willebrand/terapia , Factor de von Willebrand/genética , Factor de von Willebrand/inmunologíaRESUMEN
BACKGROUND: Polyphosphate, a phosphate polymer released by activated platelets, has recently been described as a potent modulator of blood coagulation and fibrinolysis. In blood plasma, polyphosphate binds to and alters the biological functions of factor XII, fibrin(ogen), thrombin and factor VII activating protease. OBJECTIVES: The aim of the present study is to investigate whether polyphosphate also binds to von Willebrand factor (VWF) and alters some of its activities. METHODS/RESULTS: When studying patients with type 1 von Willebrand disease (VWD) and their healthy relatives, we discovered a significant correlation between von Willebrand factor (VWF) and platelet polyphosphate levels. We have also found polyphosphate in preparations of VWF isolated from normal platelets and plasma. Surface plasmon resonance and electrophoretic mobility assays indicated that polyphosphate interacts with VWF in a dose- and time-dependent manner. Treatment of normal plasma with active exopolyphosphatase decreased the VWF ristocetin cofactor (VWF:RCo) activity, a functional measure of VWF binding to platelet glycoprotein receptor Ib. VWF collagen binding and multimerization were unaltered after polyphosphate depletion. Moreover, addition of polyphosphate increased the deficient VWF:RCo activity presented by plasma from patients with type 1 VWD. CONCLUSIONS: Our results reveal that a new role is played by polyphosphate in hemostasis by its interaction with VWF, and suggest that this polymer may be effective in the treatment of some types of VWD.
Asunto(s)
Complejo GPIb-IX de Glicoproteína Plaquetaria/química , Polifosfatos/química , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/química , Ácido Anhídrido Hidrolasas/química , Coagulación Sanguínea , Plaquetas/citología , Colágeno/química , Factor XII/química , Fibrinógeno/química , Fibrinólisis , Humanos , Microscopía Confocal , Polímeros/química , Unión Proteica , Serina Endopeptidasas/química , Resonancia por Plasmón de Superficie , Trombina/química , Enfermedades de von Willebrand/inmunologíaRESUMEN
The comparative analysis of expression level of FCRL1 gene encoding human B-cell surface receptor in healthy individuals and patients with autoimmune diseases was carried out. For the expression estimation we used results of DNA dot-hybridization on the membranes, containing cDNA samples from subpopulations of blood cells of patients with autoimmune diseases. The quantitative estimation of hybridization signals showed that expression level of FCRL1 gene in peripheral blood B-lymphocytes was significantly higher in patients with a multiple sclerosis, lupus anticoagulans, Takayasu's arteritis and also in von Willebrand disease than in healthy individuals. FCRL1-specific monoclonal and polyclonal antibodies were raised. They were proven to detect FCRL1 in Western blotting, immunohistochemistry and flow cytometry. It was found that FCRL1 is expressed on the surface of CD19+ mature B-cells. In tonsil FCRL1-positive cells were located in crypt area: in mantle zone of secondary lymphoid follicles and among cells of lymphoepithelium. FCRL1-positive cells were also found in B-cell follicles of the spleen.
Asunto(s)
Linfocitos B/metabolismo , Inhibidor de Coagulación del Lupus/genética , Proteínas de la Membrana/genética , Esclerosis Múltiple/genética , Arteritis de Takayasu/genética , Enfermedades de von Willebrand/genética , Anticuerpos/inmunología , Antígenos CD19/inmunología , Autoinmunidad , Linfocitos B/inmunología , Western Blotting , Estudios de Casos y Controles , ADN Complementario/análisis , Expresión Génica , Humanos , Inmunohistoquímica , Inhibidor de Coagulación del Lupus/inmunología , Esclerosis Múltiple/inmunología , Esclerosis Múltiple/patología , Tonsila Palatina/inmunología , Tonsila Palatina/metabolismo , Bazo/inmunología , Bazo/metabolismo , Arteritis de Takayasu/inmunología , Arteritis de Takayasu/patología , Enfermedades de von Willebrand/inmunología , Enfermedades de von Willebrand/patologíaRESUMEN
During the past 25 years, our knowledge concerning the pathogenesis, diagnostic strategies, and treatment of von Willebrand disease (VWD) has increased significantly. Following the immunological differentiation of factor VIII (FVIII) and von Willebrand factor (VWF) in the 1970s and the cloning of the FVIII and VWF genes in the mid-1980s, substantial progress has been made in our understanding of this, the most common inherited bleeding disorder. We now recognize that VWD represents a range of genetic diseases all with the clinical endpoint of increased mucocutaneous bleeding. The molecular pathology of Type 2 and 3 VWD is now comprehensively documented and involves rare sequence variants at the VWF locus. In contrast, the genetic causation of Type 1 disease remains incompletely defined and in many cases appears to involve genetic determinants in addition to or instead of VWF. The diagnostic triad of a personal history of excessive mucocutaneous bleeding, laboratory tests for VWF that are consistent with VWD, and a family history of the condition remain the keystone to VWD identification. In the laboratory, measurement of VWF antigen and function continue to be the most important diagnostic studies, and while our understanding of the molecular genetic pathology of VWD has advanced considerably in the past decade, genetic testing as a component of diagnosis is limited to certain distinct subtypes of the disorder. Treatment of VWD has been relatively unchanged for the past decade and continues to involve either stimulation of the release of intrinsic VWF with desmopressin or the infusion of VWF concentrates.